This is a list of all content pages that are marked reviewed, but after the review it was subsequently edited. Presumably these pages need to be reviewed again.
5925 reviews are up to date. 3793 reviews are stale and are listed below.
- The gut microbiota in conventional and serrated precursors of colorectal cancer
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 1
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 2
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 3
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 4
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 5
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 5/Signature 1
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 6
- The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 7
- Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas
- Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas/Experiment 1
- Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas/Experiment 2
- Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations
- Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations/Experiment 1
- Gut microbiome alterations in patients with stage 4 hepatitis C
- Gut microbiome alterations in patients with stage 4 hepatitis C/Experiment 1
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 1
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 2
- Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
- Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease/Experiment 1
- Pyrosequencing study of fecal microflora of autistic and control children
- Pyrosequencing study of fecal microflora of autistic and control children/Experiment 1
- Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults
- Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults/Experiment 1
- A comprehensive analysis of breast cancer microbiota and host gene expression
- A comprehensive analysis of breast cancer microbiota and host gene expression/Experiment 1
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 2
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 2/Signature 1
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
- Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study
- Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 1
- Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 2
- Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 3
- Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 4
- The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia
- The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia/Experiment 1
- The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia/Experiment 2
- The tongue microbiome in healthy subjects and patients with intra-oral halitosis
- The tongue microbiome in healthy subjects and patients with intra-oral halitosis/Experiment 1
- The tongue microbiome in healthy subjects and patients with intra-oral halitosis/Experiment 1/Signature 2
- The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study
- The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study/Experiment 1
- Melatonin prevents obesity through modulation of gut microbiota in mice
- Melatonin prevents obesity through modulation of gut microbiota in mice/Experiment 1
- Melatonin prevents obesity through modulation of gut microbiota in mice/Experiment 2
- Altered gut microbiota profile in patients with generalized anxiety disorder
- Altered gut microbiota profile in patients with generalized anxiety disorder/Experiment 1
- Altered gut microbiota profile in patients with generalized anxiety disorder/Experiment 2
- High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice
- High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 1
- High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 2
- High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 3
- High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 3/Signature 2
- Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study
- Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study/Experiment 1
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota/Experiment 1
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota/Experiment 2
- 16S gut community of the Cameron County Hispanic Cohort
- 16S gut community of the Cameron County Hispanic Cohort/Experiment 1
- Analysis of Gut Microbiota in Patients with Parkinson's Disease
- Analysis of Gut Microbiota in Patients with Parkinson's Disease/Experiment 1
- Gut microbiome alterations in Alzheimer's disease
- Gut microbiome alterations in Alzheimer's disease/Experiment 1
- Gut microbiome alterations in Alzheimer's disease/Experiment 1/Signature 1
- Gut microbiome alterations in Alzheimer's disease/Experiment 1/Signature 2
- Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function
- Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function/Experiment 1
- Microbiome dynamics of human epidermis following skin barrier disruption
- Microbiome dynamics of human epidermis following skin barrier disruption/Experiment 1
- Intestinal Microbiota Is Influenced by Gender and Body Mass Index
- Intestinal Microbiota Is Influenced by Gender and Body Mass Index/Experiment 1
- Intestinal Microbiota Is Influenced by Gender and Body Mass Index/Experiment 2
- Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota
- Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota/Experiment 1
- Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota/Experiment 2
- Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome
- Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1
- Altered fecal microbiota composition in patients with major depressive disorder
- Altered fecal microbiota composition in patients with major depressive disorder/Experiment 1
- Altered fecal microbiota composition in patients with major depressive disorder/Experiment 2
- High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients
- High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 1
- High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 2
- High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 3
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1/Signature 2
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 2
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 2/Signature 2
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 3
- Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 3/Signature 1
- Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests
- Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests/Experiment 1
- Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing
- Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing/Experiment 1
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 1
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 2
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 3
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 4
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 5
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 6
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 7
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 8
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 9
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 10
- A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 11
- Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing
- Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing/Experiment 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 1/Signature 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 1/Signature 2
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 2
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 2/Signature 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 2/Signature 2
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 3
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 4
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 4/Signature 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 5
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 5/Signature 1
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 5/Signature 2
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 6
- Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 6/Signature 1
- Dysbiosis signature of fecal microbiota in colorectal cancer patients
- Dysbiosis signature of fecal microbiota in colorectal cancer patients/Experiment 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2/Signature 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3/Signature 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 4
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 5
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 6
- Gut microbiome in ADHD and its relation to neural reward anticipation
- Gut microbiome in ADHD and its relation to neural reward anticipation/Experiment 1
- Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response
- Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 1
- Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 1/Signature 2
- Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function
- Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function/Experiment 1
- Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease
- Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 1
- Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 1/Signature 1
- Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 1/Signature 2
- Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 2
- Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations
- Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations/Experiment 1
- An intermittent hypercaloric diet alters gut microbiota, prefrontal cortical gene expression and social behaviours in rats
- An intermittent hypercaloric diet alters gut microbiota, prefrontal cortical gene expression and social behaviours in rats/Experiment 1
- Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study
- Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 1
- Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study
- Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 1
- Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 2
- Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 2/Signature 2
- Obesity Alters the Microbial Community Profile in Korean Adolescents
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 1
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 2
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 3
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 4
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 5
- Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 6
- Characterization of the salivary microbiome in people with obesity
- Characterization of the salivary microbiome in people with obesity/Experiment 1
- Characterization of the salivary microbiome in people with obesity/Experiment 1/Signature 1
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers/Experiment 1
- Gut microbiota in patients after surgical treatment for colorectal cancer
- Gut microbiota in patients after surgical treatment for colorectal cancer/Experiment 1
- Gut microbiota in patients after surgical treatment for colorectal cancer/Experiment 2
- Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing
- Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing/Experiment 1
- Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing/Experiment 2
- Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
- Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)/Experiment 1
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 1
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 1/Signature 1
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 1/Signature 2
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 2
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 2/Signature 1
- Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 2/Signature 2
- Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse
- Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse/Experiment 1
- Diversified microbiota of meconium is affected by maternal diabetes status
- Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 1
- Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 2
- Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 3
- The microbiome of the oral mucosa in irritable bowel syndrome
- The microbiome of the oral mucosa in irritable bowel syndrome/Experiment 1
- The microbiome of the oral mucosa in irritable bowel syndrome/Experiment 2
- The early infant gut microbiome varies in association with a maternal high-fat diet
- The early infant gut microbiome varies in association with a maternal high-fat diet/Experiment 1
- The early infant gut microbiome varies in association with a maternal high-fat diet/Experiment 2
- Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat
- Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat/Experiment 1
- Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study
- Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study/Experiment 1
- Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study/Experiment 2
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 1
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 2
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 3
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 4
- Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease
- Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 1
- Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 1/Signature 1
- Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section
- Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 1
- Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 2
- Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 3
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 1/Signature 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 1/Signature 2
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 2
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 2/Signature 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 2/Signature 2
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 3
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 3/Signature 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 4
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 4/Signature 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 4/Signature 2
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 5
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 5/Signature 1
- Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 5/Signature 2
- Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis
- Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis/Experiment 1
- Meconium microbiome associates with the development of neonatal jaundice
- Meconium microbiome associates with the development of neonatal jaundice/Experiment 1
- Meconium microbiome associates with the development of neonatal jaundice/Experiment 2
- New evidences on the altered gut microbiota in autism spectrum disorders
- New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 1
- New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 2
- New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 3
- New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 4
- A taxonomic signature of obesity in a large study of American adults
- A taxonomic signature of obesity in a large study of American adults/Experiment 1
- A taxonomic signature of obesity in a large study of American adults/Experiment 1/Signature 1
- A taxonomic signature of obesity in a large study of American adults/Experiment 1/Signature 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 2/Signature 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 3
- A taxonomic signature of obesity in a large study of American adults/Experiment 3/Signature 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 4
- A taxonomic signature of obesity in a large study of American adults/Experiment 4/Signature 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 5
- A taxonomic signature of obesity in a large study of American adults/Experiment 5/Signature 2
- A taxonomic signature of obesity in a large study of American adults/Experiment 6
- A taxonomic signature of obesity in a large study of American adults/Experiment 6/Signature 2
- Body Mass Index Differences in the Gut Microbiota Are Gender Specific
- Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 1
- Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 2
- Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 3
- Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 4
- Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits
- Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 1
- Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 2
- Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 3
- Meconium microbiome analysis identifies bacteria correlated with premature birth
- Meconium microbiome analysis identifies bacteria correlated with premature birth/Experiment 1
- Meconium microbiome analysis identifies bacteria correlated with premature birth/Experiment 2
- Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China
- Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China/Experiment 1
- Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome
- Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome/Experiment 1
- Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome/Experiment 2
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 1
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 1/Signature 1
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 1/Signature 2
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 2
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 3
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 3/Signature 1
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 3/Signature 2
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 4
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 4/Signature 1
- Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 4/Signature 2
- Disordered microbial communities in the upper respiratory tract of cigarette smokers
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 2
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 3
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 4
- Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children
- Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children/Experiment 1
- Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
- Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort/Experiment 1
- Chronic Early-life Stress in Rat Pups Alters Basal Corticosterone, Intestinal Permeability, and Fecal Microbiota at Weaning: Influence of Sex/Experiment 1
- Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption
- Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption/Experiment 1
- Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption/Experiment 2
- Fecal microbiota imbalance in Mexican children with type 1 diabetes
- Fecal microbiota imbalance in Mexican children with type 1 diabetes/Experiment 1
- Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota
- Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota/Experiment 1
- Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota/Experiment 2
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life
- Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 1
- Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 2
- Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 3
- Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 4
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 1
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 2
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 3
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 4
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 5
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 6
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 7
- Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 8
- Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study
- Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study/Experiment 1
- Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study/Experiment 2
- Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1
- Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1/Signature 1
- Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function
- Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 1
- Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 2
- Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section
- Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section/Experiment 1
- Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
- Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 1
- Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 2
- Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 3
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 1
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 1/Signature 1
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 2
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 2/Signature 1
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 3
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 3/Signature 1
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 4
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 4/Signature 1
- Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 4/Signature 2
- Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing
- Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 1
- Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 2
- Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 3
- Gut microbiota and overweight in 3-year old children
- Gut microbiota and overweight in 3-year old children/Experiment 1
- Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population
- Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population/Experiment 1
- Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients
- Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 1
- Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 2
- Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 3
- Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 4
- Blood Microbiome Profile in CKD : A Pilot Study
- Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1
- Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1/Signature 1
- Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1/Signature 2
- Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study
- Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study/Experiment 1
- Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study/Experiment 2
- Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii
- Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii/Experiment 1
- The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes
- The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes/Experiment 1
- Sex differences in gut microbiota in patients with major depressive disorder
- Sex differences in gut microbiota in patients with major depressive disorder/Experiment 1
- Sex differences in gut microbiota in patients with major depressive disorder/Experiment 2
- Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder
- Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 1
- Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 2
- Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 3
- Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1/Signature 1
- The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1
- The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 1
- The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 2
- Gut Dysbiosis in Patients with Anorexia Nervosa/Experiment 1
- Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints/Experiment 1
- Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints/Experiment 2
- Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints/Experiment 2/Signature 2
- Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia/Experiment 1
- Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1
- Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1
- Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study
- Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study/Experiment 1
- Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 1
- Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 1/Signature 2
- Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 2
- The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding
- The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 1
- The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 1/Signature 1
- The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 2
- Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease
- Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 1
- Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 2
- Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 3
- Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels
- Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels/Experiment 1
- Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels/Experiment 2
- Subgingival Microbiome of Gingivitis in Chinese Undergraduates
- Subgingival Microbiome of Gingivitis in Chinese Undergraduates/Experiment 1
- Subgingival Microbiome of Gingivitis in Chinese Undergraduates/Experiment 1/Signature 1
- Subgingival Microbiome of Gingivitis in Chinese Undergraduates/Experiment 1/Signature 2
- Microbial dysbiosis is associated with human breast cancer/Experiment 1
- High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats
- High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats/Experiment 1
- The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study
- The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 1
- The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 2
- The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 3
- Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing
- Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing/Experiment 1
- Changes in the salivary microbiota of oral leukoplakia and oral cancer
- Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 1
- Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 2
- Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 3
- Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption/Experiment 1
- Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption/Experiment 2
- Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1
- Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2
- Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 1
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 2
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 3
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 4
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 5
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 6
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 7
- Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 8
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 1
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 2
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 2/Signature 1
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 3
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 3/Signature 1
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 4
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 5
- Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 6
- Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults
- Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults/Experiment 1
- Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet
- Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet/Experiment 1
- Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet/Experiment 2
- Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project
- Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 2
- Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1
- Dysbiosis of the Gut Microbiome in Lung Cancer/Experiment 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1/Signature 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1/Signature 2
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 2
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 2/Signature 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 3
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 3/Signature 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4/Signature 1
- Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4/Signature 2
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 1
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 2
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 3
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 4
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 5
- Alterations of the human gut microbiome in multiple sclerosis/Experiment 6
- 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment
- 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 1
- 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 1/Signature 1
- 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 2
- 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 3
- The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis
- The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis/Experiment 1
- The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis/Experiment 2
- Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 1
- Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 1/Signature 2
- Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 2
- Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 2/Signature 2
- Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 3
- The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects
- The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects/Experiment 1
- Variations in oral microbiota associated with oral cancer
- Variations in oral microbiota associated with oral cancer/Experiment 1
- Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma
- Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma/Experiment 1
- Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma/Experiment 2
- The gut microbiome of Mexican children affected by obesity/Experiment 1
- The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2
- Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer
- Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer/Experiment 1
- Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer/Experiment 2
- Breast cancer in postmenopausal women is associated with an altered gut metagenome
- Breast cancer in postmenopausal women is associated with an altered gut metagenome/Experiment 1
- Altered diversity and composition of the gut microbiome in patients with cervical cancer/Experiment 1
- Altered diversity and composition of the gut microbiome in patients with cervical cancer/Experiment 2
- The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2
- Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers
- Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers/Experiment 1
- Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers/Experiment 2
- Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China
- Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China/Experiment 1
- Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China/Experiment 2
- Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1
- Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 2
- Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2
- Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 1
- Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 2
- Alterations of fecal bacterial communities in patients with lung cancer/Experiment 2
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 1
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 2
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 3
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4/Signature 1
- Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 5
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 1
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 2
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 1
- The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 2
- Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1
- Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease/Experiment 1
- Altered gut microbiota and microbial biomarkers associated with chronic kidney disease/Experiment 1
- Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1
- Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 1
- Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 2
- Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2
- Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 1
- Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 1/Signature 1
- Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 2
- Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 3
- Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1
- Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 2
- Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 3
- Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4
- Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 1
- Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 2
- Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3
- Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 4
- Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 1
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 2
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 1
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 2
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 1
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 2
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 4
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 4/Signature 1
- Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 4/Signature 2
- Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China/Experiment 1
- Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China/Experiment 2
- Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 1
- Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 2
- Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 3
- Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 1
- Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 2
- Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota/Experiment 1
- Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1
- A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1/Signature 2
- Gut microbiota shifts in patients with gastric cancer in perioperative period/Experiment 1
- Gut microbiota shifts in patients with gastric cancer in perioperative period/Experiment 2
- Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2
- Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2/Signature 1
- Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2/Signature 2
- Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 1
- Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 2
- Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 3
- Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 4
- Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients/Experiment 1
- Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production/Experiment 1
- Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1
- The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1
- Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project/Experiment 1
- Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project/Experiment 2
- Gut microbiota dysbiosis is associated with Henoch-Schönlein Purpura in children/Experiment 1
- Lower airway microbiota and mycobiota in children with severe asthma/Experiment 1
- The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ/Experiment 1
- The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ/Experiment 1/Signature 1
- Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1
- Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1
- Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota/Experiment 1
- Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota/Experiment 2
- Gut microbiota analysis and its significance in vasovagal syncope in children/Experiment 1
- Increased Abundance of Clostridium and Fusobacterium in Gastric Microbiota of Patients with Gastric Cancer in Taiwan/Experiment 1
- Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis/Experiment 1
- Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis/Experiment 2
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 1
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 1
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 2
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 2
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 3
- Altered fecal microbiota composition associated with food allergy in infants/Experiment 4
- Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1
- Gut Microbiota Signatures in Gestational Anemia/Experiment 1
- Gut Microbiota Signatures in Gestational Anemia/Experiment 1/Signature 1
- Gut Microbiota Signatures in Gestational Anemia/Experiment 2
- Gut Microbiota Signatures in Gestational Anemia/Experiment 2/Signature 1
- Association of dietary fibre intake and gut microbiota in adults
- Association of dietary fibre intake and gut microbiota in adults/Experiment 1
- Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1
- Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2
- Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 2
- Early-life gut microbiome composition and milk allergy resolution/Experiment 1
- Early-Life Events, Including Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the Developing Gut Microbiota/Experiment 1
- Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 1
- Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 4
- Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma/Experiment 1
- Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma/Experiment 2
- Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma/Experiment 3
- Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1
- Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2
- Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1
- Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1/Signature 2
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 1
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 1/Signature 1
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 1/Signature 2
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 2
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 3
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 4
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 4/Signature 1
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 5
- Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 6
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 1
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 2
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 3
- Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population/Experiment 1
- Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population/Experiment 2
- Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6
- The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1
- Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1
- Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1/Signature 1
- Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2/Signature 1
- Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3/Signature 1
- Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 12/Signature 1
- An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia/Experiment 1
- Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 1
- Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 2
- Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 1
- Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 2
- Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1
- Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 1
- Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 2
- Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 1
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 2
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3/Signature 1
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3/Signature 2
- Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
- Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 1
- Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 1/Signature 2
- Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 2
- Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 3
- Early-life gut microbiome and egg allergy/Experiment 1
- Early-life gut microbiome and egg allergy/Experiment 2
- Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1
- Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1/Signature 1
- Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2
- Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 1
- Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 2
- Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1
- Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 2
- Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 3
- Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 3/Signature 1
- Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 4/Signature 1
- Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 5/Signature 1
- Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 6/Signature 2
- 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1
- Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2
- Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5
- The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection
- The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection/Experiment 1
- The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection/Experiment 2
- Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1
- Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 1
- Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 2
- The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients/Experiment 1
- The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients/Experiment 1/Signature 2
- Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions
- Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 1
- Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 2
- Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 3
- Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 3/Signature 1
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 1
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 1/Signature 1
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 1/Signature 2
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 2
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 2/Signature 1
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 2/Signature 2
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3/Signature 1
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3/Signature 2
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 4
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 5
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 6
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 8
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 9
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 10
- Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 11
- Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis/Experiment 1
- Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis/Experiment 2
- Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis/Experiment 1
- Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis/Experiment 1/Signature 1
- Bacterial biogeography of adult airways in atopic asthma
- Bacterial biogeography of adult airways in atopic asthma/Experiment 1
- Bacterial biogeography of adult airways in atopic asthma/Experiment 2
- Bacterial biogeography of adult airways in atopic asthma/Experiment 3
- Bacterial biogeography of adult airways in atopic asthma/Experiment 3/Signature 1
- Bacterial biogeography of adult airways in atopic asthma/Experiment 3/Signature 2
- Bacterial biogeography of adult airways in atopic asthma/Experiment 4
- Bacterial biogeography of adult airways in atopic asthma/Experiment 5
- Bacterial biogeography of adult airways in atopic asthma/Experiment 6
- Bacterial biogeography of adult airways in atopic asthma/Experiment 7
- Bacterial biogeography of adult airways in atopic asthma/Experiment 7/Signature 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 1/Signature 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 1/Signature 2
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 2
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 2/Signature 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 2/Signature 2
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 3
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 3/Signature 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 3/Signature 2
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 4
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 4/Signature 1
- A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 4/Signature 2
- Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women
- Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1
- Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1/Signature 1
- Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1/Signature 2
- HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 1
- HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 2
- HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 3
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 1
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 2
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 3
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4/Signature 1
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 5
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 6
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 7
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 8
- Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 9
- Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china
- Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china/Experiment 1
- Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china/Experiment 1/Signature 1
- Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection
- Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 1
- Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 2
- Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 2/Signature 2
- Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2
- Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 5
- Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 6
- Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1
- Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1/Signature 1
- Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 1/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 1/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 2/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 2/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 3
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 3/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 3/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 4
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 4/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 4/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 5
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 5/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 5/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 6
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 6/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 6/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 7
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 7/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 7/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 8
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 8/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 9
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 9/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 9/Signature 2
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 10
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 10/Signature 1
- Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 10/Signature 2
- Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis/Experiment 1
- Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1
- Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2
- Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 3
- Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 4
- Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers/Experiment 1
- Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1
- Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2
- Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 1
- Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity
- Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity/Experiment 1
- The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis
- The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis/Experiment 1
- Carious status and supragingival plaque microbiota in hemodialysis patients/Experiment 1
- Carious status and supragingival plaque microbiota in hemodialysis patients/Experiment 2
- Carious status and supragingival plaque microbiota in hemodialysis patients/Experiment 2/Signature 1
- Carious status and supragingival plaque microbiota in hemodialysis patients/Experiment 4
- Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1/Signature 1
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2/Signature 1
- Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2/Signature 2
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 1
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 1/Signature 1
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 2
- Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 2/Signature 2
- Phenylketonuric diet negatively impacts on butyrate production/Experiment 1
- Association of suboptimal health status with intestinal microbiota in Chinese youths/Experiment 1
- Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1
- Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2
- Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3
- Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4
- Disrupted tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic hematopoietic stem cell transplantation/Experiment 1
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 1
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 1/Signature 2
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 2
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 3
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 4
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 5
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 6
- Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 7
- Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2
- Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3
- Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4
- Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls
- Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1
- Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1/Signature 1
- Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1/Signature 2
- Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria/Experiment 1
- Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria/Experiment 2
- Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women
- Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women/Experiment 1
- Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women/Experiment 2
- Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 2
- Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 3
- Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota/Experiment 1
- Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 2
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1/Signature 1
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1/Signature 2
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 2
- Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 3
- The nasal microbiome in asthma
- The nasal microbiome in asthma/Experiment 3
- The nasal microbiome in asthma/Experiment 4
- The nasal microbiome in asthma/Experiment 5
- Chemotherapy-driven dysbiosis in the intestinal microbiome/Experiment 1
- Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial
- Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial/Experiment 1
- Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial/Experiment 1/Signature 1
- Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women/Experiment 1
- Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1
- Protection of the Human Gut Microbiome From Antibiotics/Experiment 1
- Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 1
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 1/Signature 1
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 1/Signature 2
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 2
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 2/Signature 1
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 2/Signature 2
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 3
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 3/Signature 1
- Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 3/Signature 2
- The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions
- The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 1
- The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 2
- The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 3
- The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 4
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 2
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 2
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 1
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10
- Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11
- Exposure to concentrated ambient PM2.5 alters the composition of gut microbiota in a murine model/Experiment 1
- Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 1
- Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 1
- Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 3
- Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients/Experiment 1
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 1
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 2
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 1
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 2
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3
- Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2
- Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 1
- Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 1
- Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 2
- Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3
- Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2
- HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa
- HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 1
- HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 2
- HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 3
- Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1
- Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants
- Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing/Experiment 1
- Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing/Experiment 2
- Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing/Experiment 2/Signature 2
- Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites/Experiment 1
- Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease/Experiment 1/Signature 1
- Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease/Experiment 1/Signature 2
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 1
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 2
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 3
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 5
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 7
- Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8
- Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation/Experiment 1
- Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 1
- Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 1/Signature 1
- Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 1/Signature 2
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1/Signature 2
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2/Signature 1
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 1
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 2
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 5/Signature 1
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 6/Signature 1
- The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 6/Signature 2
- A study of the correlation between obesity and intestinal flora in school-age children/Experiment 1
- Correlation between body mass index and faecal microbiota from children/Experiment 2
- Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 1/Signature 1
- Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1
- Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 2
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 1
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 1/Signature 1
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 2
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 2/Signature 1
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 2/Signature 2
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 3
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 3/Signature 1
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 4
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 4/Signature 1
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 4/Signature 2
- The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 1
- The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 2
- Differences in gut microbiota composition between obese and lean children: a cross-sectional study/Experiment 1
- Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 1
- High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition/Experiment 1
- Cigarette smoking and the oral microbiome in a large study of American adults
- Cigarette smoking and the oral microbiome in a large study of American adults/Experiment 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 1/Signature 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 2
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 2/Signature 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 3
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 3/Signature 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 1
- Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 2
- Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1
- The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1
- Analysis of the effect of smoking on the buccal microbiome using next-generation sequencing technology/Experiment 1
- A Metabologenomic Approach Reveals Changes in the Intestinal Environment of Mice Fed on American Diet/Experiment 1
- A Metabologenomic Approach Reveals Changes in the Intestinal Environment of Mice Fed on American Diet/Experiment 1/Signature 1
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 1
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 1/Signature 1
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 2
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 2/Signature 1
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3/Signature 1
- Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5/Signature 1
- Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 2
- Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 3/Signature 1
- Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 3/Signature 2
- Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 1
- Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 2
- Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects/Experiment 1
- Short-term effect of antibiotics on human gut microbiota/Experiment 1
- Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 1
- Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 2
- Short-term effect of antibiotics on human gut microbiota/Experiment 2
- Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 1
- Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 2
- Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection
- Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 1
- Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 2
- Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 3
- Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 1
- Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 1/Signature 2
- Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 2
- Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
- Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 1
- Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 2
- Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 3
- Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 4
- Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study
- Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study/Experiment 1
- Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study/Experiment 2
- HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women
- HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women/Experiment 1
- HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women/Experiment 2
- Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1
- Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2
- Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3
- The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 2
- The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1
- Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods/Experiment 1
- Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods/Experiment 2
- Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1
- Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 1
- Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 2
- Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1
- Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2
- Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 1
- Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3
- Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3/Signature 1
- Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1
- Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 1
- Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 2
- Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 3
- Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 4
- Infant airway microbiota and topical immune perturbations in the origins of childhood asthma/Experiment 1
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1/Signature 1
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1/Signature 2
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 2/Signature 1
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3/Signature 1
- Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3/Signature 2
- Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 1
- Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 2
- Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 3
- Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1
- Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 2
- Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1
- Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 1
- Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2
- Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1
- Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 1
- Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2
- Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood/Experiment 1
- Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood/Experiment 2
- Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1
- Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2
- Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3
- Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 1
- Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 2
- Variations in early gut microbiome are associated with childhood eczema
- Variations in early gut microbiome are associated with childhood eczema/Experiment 1
- Variations in early gut microbiome are associated with childhood eczema/Experiment 2
- Variations in early gut microbiome are associated with childhood eczema/Experiment 3
- Variations in early gut microbiome are associated with childhood eczema/Experiment 4
- Variations in early gut microbiome are associated with childhood eczema/Experiment 5
- Variations in early gut microbiome are associated with childhood eczema/Experiment 6
- Variations in early gut microbiome are associated with childhood eczema/Experiment 7
- Variations in early gut microbiome are associated with childhood eczema/Experiment 7/Signature 1
- Variations in early gut microbiome are associated with childhood eczema/Experiment 8
- Variations in early gut microbiome are associated with childhood eczema/Experiment 9
- Variations in early gut microbiome are associated with childhood eczema/Experiment 10
- Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis/Experiment 1
- Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers/Experiment 1
- Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers/Experiment 1/Signature 2
- Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1
- Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 1
- Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 2
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 1
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 2
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 3
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 3/Signature 1
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 4
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 4/Signature 2
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5/Signature 1
- Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5/Signature 2
- The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study/Experiment 1
- Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 4
- Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1
- Gut microbiota and plasma metabolites associated with diabetes in women with, or at high risk for, HIV infection/Experiment 1
- Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 1
- Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 3
- Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 1
- Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 2
- Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2
- Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2/Signature 1
- Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study/Experiment 1
- Fecal microbiome signatures of pancreatic cancer patients
- Fecal microbiome signatures of pancreatic cancer patients/Experiment 1
- Fecal microbiome signatures of pancreatic cancer patients/Experiment 3
- Fecal microbiome signatures of pancreatic cancer patients/Experiment 4
- Fecal microbiome signatures of pancreatic cancer patients/Experiment 4/Signature 2
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 1
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 2
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 3
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 4
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 5
- Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 6
- Alterations of gut microbiome in autoimmune hepatitis/Experiment 1
- High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2
- High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 3
- Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19
- Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 1
- Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 2
- Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 3
- Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 4
- Alterations in Gastric Microbial Communities Are Associated with Risk of Gastric Cancer in a Korean Population: A Case-Control Study/Experiment 1
- Alterations in Gastric Microbial Communities Are Associated with Risk of Gastric Cancer in a Korean Population: A Case-Control Study/Experiment 1/Signature 2
- Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19
- Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19/Experiment 1
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 1
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 1/Signature 1
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 2
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 3
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 4
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 5
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 6
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 7
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 8
- Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 9
- Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection
- Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection/Experiment 1
- Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2
- Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1
- Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2
- Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3
- Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4
- Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1
- Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 2
- Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2
- Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 3
- Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection/Experiment 1
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 1
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 2
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 3
- Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans/Experiment 1
- Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 1
- Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 2
- Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza
- Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 1
- Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2
- Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 3
- Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1
- Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 1
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 1/Signature 1
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 1/Signature 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 2/Signature 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 3
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 3/Signature 1
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 3/Signature 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5/Signature 1
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5/Signature 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6/Signature 1
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6/Signature 2
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 7
- Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1
- Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 1
- Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 2
- Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 2
- Modulation of potential respiratory pathogens by pH1N1 viral infection
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 1
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 2
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 1
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 2
- Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 3
- Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients
- Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1
- Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1/Signature 1
- Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1/Signature 2
- The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort
- The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 1
- The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 2
- The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 3
- The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 4
- Tumour-associated and non-tumour-associated microbiota in colorectal cancer
- Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1
- Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1/Signature 1
- Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1/Signature 2
- Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis
- Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 1
- Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 2
- Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 1
- Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 2
- Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 3
- Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 4
- Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 5
- Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai
- Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai/Experiment 1
- Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai/Experiment 2
- Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients
- Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients/Experiment 1
- Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients/Experiment 1/Signature 1
- Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 2
- Alterations in the human oral and gut microbiomes and lipidomics in COVID-19
- Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 1
- Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 2
- Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 3
- Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes/Experiment 1
- Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes/Experiment 2
- Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes/Experiment 3
- Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 1
- Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 1/Signature 1
- Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 2
- Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 3
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1/Signature 2
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 2
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 3
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 5
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 6
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 7
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 8
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 9
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 10
- Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 11
- Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19
- Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19/Experiment 1
- Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
- Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1
- Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation
- 16S rRNA gene amplicon sequencing of gut microbiota in gestational diabetes mellitus and their correlation with disease risk factors/Experiment 1
- Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases
- Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases/Experiment 1
- Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases/Experiment 1/Signature 1
- Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery/Experiment 1
- Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery/Experiment 1/Signature 2
- Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19
- Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 1
- Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 2
- Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 3
- Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1
- Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2
- Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3
- Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients
- Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients/Experiment 1
- Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients/Experiment 2
- Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization
- Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 1
- Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 2
- Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 3
- Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19
- Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 1
- Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 2
- Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 3
- Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever
- Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever/Experiment 1
- Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever/Experiment 2
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1/Signature 1
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1/Signature 2
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 2
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 2/Signature 1
- Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 3
- Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome/Experiment 1
- 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19
- 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 1
- 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 2
- 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 3
- Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1
- Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy/Experiment 1
- The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1
- Characteristics of the gut microbiome in patients with prediabetes and type 2 diabetes/Experiment 1
- Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18
- Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 1
- Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 1/Signature 1
- Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 2
- Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 2/Signature 2
- Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 1
- Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 1/Signature 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 2
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 3
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 4
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 2
- Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 1
- Comparative analysis of racial differences in breast tumor microbiome
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 1
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 2
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 3
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 4
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 5
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 6
- Comparative analysis of racial differences in breast tumor microbiome/Experiment 6/Signature 2
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 1
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 1/Signature 2
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 2
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 3
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 4
- The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
- The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin/Experiment 1
- The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin/Experiment 2
- Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features/Experiment 1
- Effects of smoking on the lower respiratory tract microbiome in mice
- Effects of smoking on the lower respiratory tract microbiome in mice/Experiment 2/Signature 1
- Effects of smoking on the lower respiratory tract microbiome in mice/Experiment 2/Signature 2
- Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients
- Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 1
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 1
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 2
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 3
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 4
- Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 5
- Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 1
- Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment/Experiment 2
- Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1
- Endometriosis induces gut microbiota alterations in mice
- Endometriosis induces gut microbiota alterations in mice/Experiment 1
- Endometriosis induces gut microbiota alterations in mice/Experiment 2
- Endometriosis induces gut microbiota alterations in mice/Experiment 2/Signature 1
- Endometriosis induces gut microbiota alterations in mice/Experiment 2/Signature 2
- Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1
- Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 1
- Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota/Experiment 1
- The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 2
- Altered Composition of Microbiota in Women with Ovarian Endometrioma: Microbiome Analyses of Extracellular Vesicles in the Peritoneal Fluid/Experiment 1
- Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1
- Correlation of fecal metabolomics and gut microbiota in mice with endometriosis/Experiment 1
- The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1
- Associations Between Endometriosis and Gut Microbiota/Experiment 1
- Associations Between Endometriosis and Gut Microbiota/Experiment 1/Signature 1
- Associations Between Endometriosis and Gut Microbiota/Experiment 2
- Effect of endometriosis on the fecal bacteriota composition of mice during the acute phase of lesion formation/Experiment 1
- Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening
- Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening/Experiment 1
- Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening/Experiment 2
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 1
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 2
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 3
- An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis/Experiment 1
- An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis/Experiment 1/Signature 1
- An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis/Experiment 1/Signature 2
- Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 1
- Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2
- Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 1
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 1
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 2
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 3
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 4
- Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
- Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1
- Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 2
- Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 1
- Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 2
- Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 6
- Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 7
- Salivary Microbiome and Cigarette Smoking: A First of Its Kind Investigation in Jordan/Experiment 1
- Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1
- Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2
- Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3
- Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4
- Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4/Signature 1
- The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 1
- The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 2
- Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1
- Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1/Signature 1
- Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1/Signature 2
- Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 1
- Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 2
- Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 3
- Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 4
- Characterization of the Human Oropharyngeal Microbiomes in SARS-CoV-2 Infection and Recovery Patients/Experiment 1
- Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals
- Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1
- Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2
- Ecological succession in the vaginal microbiota during pregnancy and birth/Experiment 1
- The association between vaginal bacterial composition and miscarriage: a nested case-control study
- The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 1
- The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 2
- The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 3
- Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 2
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 1
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 2
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 3
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 4
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 5
- Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)/Experiment 6
- Role of dietary fiber in the recovery of the human gut microbiome and its metabolome
- Role of dietary fiber in the recovery of the human gut microbiome and its metabolome/Experiment 1
- The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1
- Body site-typical microbiome signatures for adults
- Body site-typical microbiome signatures for adults/Experiment 1
- Body site-typical microbiome signatures for adults/Experiment 2
- Body site-typical microbiome signatures for adults/Experiment 3
- Body site-typical microbiome signatures for adults/Experiment 4
- Body site-typical microbiome signatures for adults/Experiment 5
- Body site-typical microbiome signatures for adults/Experiment 6
- Body site-typical microbiome signatures for adults/Experiment 7
- Body site-typical microbiome signatures for adults/Experiment 8
- Body site-typical microbiome signatures for adults/Experiment 9
- Body site-typical microbiome signatures for adults/Experiment 10
- Body site-typical microbiome signatures for adults/Experiment 10/Signature 1
- Body site-typical microbiome signatures for adults/Experiment 11
- The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 2/Signature 1
- Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1
- Gut Microbiome of Healthy and Arthritic Dogs
- Gut Microbiome of Healthy and Arthritic Dogs/Experiment 1
- Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status/Experiment 1
- Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status/Experiment 2
- Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status/Experiment 3
- Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status/Experiment 4
- Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma
- Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1/Signature 1
- Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1/Signature 2
- Analysis of the Gut Microflora in Patients With Parkinson's Disease/Experiment 2
- Analysis of the Gut Microflora in Patients With Parkinson's Disease/Experiment 3
- Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer
- Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer/Experiment 1
- Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis/Experiment 1
- Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study
- Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study/Experiment 1
- Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study/Experiment 2
- Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing
- Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing/Experiment 1
- Antibiotics at birth and later antibiotic courses: effects on gut microbiota
- Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1
- Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1/Signature 1
- Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1/Signature 2
- Human gut microbiome and risk for colorectal cancer/Experiment 1
- Human gut microbiome and risk for colorectal cancer/Experiment 1/Signature 1
- Sex effects in the association between airway microbiome and asthma/Experiment 1
- Sex effects in the association between airway microbiome and asthma/Experiment 1/Signature 1
- Sex effects in the association between airway microbiome and asthma/Experiment 2
- Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 1
- Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 2
- Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3
- Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3/Signature 1
- Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3/Signature 2
- Altered composition of the gut microbiome in patients with drug-resistant epilepsy
- Altered composition of the gut microbiome in patients with drug-resistant epilepsy/Experiment 1
- Altered composition of the gut microbiome in patients with drug-resistant epilepsy/Experiment 2
- Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer/Experiment 1
- Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer/Experiment 2
- Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1
- Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study/Experiment 1
- Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1/Signature 1
- The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 1
- Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 1
- Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 3
- Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1
- Evolution of the gut microbiome following acute HIV-1 infection/Experiment 1
- Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 1
- Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 2
- Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation/Experiment 1
- Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome/Experiment 1
- Oral microbiome in HIV-associated periodontitis/Experiment 1
- Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1
- Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 2
- Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 3
- Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 4
- The semen microbiome and its relationship with local immunology and viral load in HIV infection/Experiment 1
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination/Experiment 1
- Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection/Experiment 1
- Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study
- Alteration of the fecal microbiota in Chinese patients with Parkinson's disease/Experiment 1
- Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease/Experiment 2
- Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens/Experiment 1
- Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens/Experiment 2
- Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
- Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease/Experiment 1
- Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease/Experiment 2
- Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model/Experiment 1
- Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model/Experiment 2
- Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1
- Body site-typical microbiome signatures for children
- Body site-typical microbiome signatures for children/Experiment 1
- Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1
- Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1/Signature 1
- Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1/Signature 2
- Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1
- Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1/Signature 3
- Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing/Experiment 1
- Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy
- Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy/Experiment 1
- Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites
- Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites/Experiment 1
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 1
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2/Signature 1
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2/Signature 2
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 3
- Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 4
- Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns
- Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon/Experiment 1
- Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 1
- Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 1/Signature 2
- Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 2
- Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy/Experiment 1
- Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 2
- Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3
- Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 4
- Fusobacterium nucleatum and T Cells in Colorectal Carcinoma/Experiment 1
- Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 1
- Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 2
- Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 3
- Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 1
- Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 2
- Microbiota disbiosis is associated with colorectal cancer/Experiment 3
- Sociodemographic variation in the oral microbiome/Experiment 6
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 1
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 1/Signature 1
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 2
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3/Signature 1
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3/Signature 2
- Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 5
- Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1
- Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 1
- Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3
- Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 1
- Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 1/Signature 1
- Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 2
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 8
- Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9
- Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress/Experiment 1
- Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1
- Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1/Signature 1
- Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 2
- Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3
- Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1
- Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2
- Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3
- The oral microbiota in colorectal cancer is distinctive and predictive
- The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1
- The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 2
- The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 3
- Gut microbiota diversity across ethnicities in the United States/Experiment 1
- Gut microbiota diversity across ethnicities in the United States/Experiment 3
- Gut microbiota diversity across ethnicities in the United States/Experiment 4
- Gut microbiota diversity across ethnicities in the United States/Experiment 5
- Gut microbiota diversity across ethnicities in the United States/Experiment 6
- Gut Microbiota Differences in Children From Distinct Socioeconomic Levels Living in the Same Urban Area in Brazil/Experiment 1
- Association Between Oral Microbiota and Cigarette Smoking in the Chinese Population
- Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis/Experiment 1/Signature 2
- Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis/Experiment 2/Signature 2
- Characterization of the gut microbiota of Papua New Guineans using reverse transcription quantitative PCR/Experiment 1
- Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 1
- Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 2
- Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 3
- Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 4
- Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 5
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 1
- Distinct gut microbiota in southeastern African and northern European infants/Experiment 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 2
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 2
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 2
- Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States/Experiment 1
- Environmental exposures and child and maternal gut microbiota in rural Malawi/Experiment 1
- The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1
- The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 1
- The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 2
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 1
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 1/Signature 1
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2/Signature 1
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2/Signature 2
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 3
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 3/Signature 2
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4/Signature 1
- Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4/Signature 2
- The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 1
- The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 2
- The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3
- Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1
- Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1/Signature 1
- Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1/Signature 2
- Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1
- Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4
- Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1
- Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 1
- Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 1
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2/Signature 1
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 4
- A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5
- Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 2
- The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer
- The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1
- Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma/Experiment 1
- Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 1
- Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 2
- Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 3
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma/Experiment 1
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma/Experiment 1/Signature 2
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 1
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 2
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 2
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 3
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 4
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 5
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6
- Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6/Signature 2
- Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1
- Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2
- Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 1
- Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1
- Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2
- Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3
- 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis
- The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1
- Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1
- Salivary microbiota and inflammation-related proteins in patients with psoriasis/Experiment 1
- Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1
- Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 3
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 4
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 4/Signature 1
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 5
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 5/Signature 1
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 6/Signature 1
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 6/Signature 2
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 9
- Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 11
- Gut microbiota in patients with Parkinson's disease in southern China/Experiment 1/Signature 2
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1/Signature 1
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1/Signature 2
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 2
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 3
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 4
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 4/Signature 1
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 5
- Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 6
- The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder/Experiment 1/Signature 2
- Diversity of vaginal microbiome and metabolome during genital infections/Experiment 1
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 1
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 2
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 3
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 4
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 4/Signature 1
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 5
- Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 6
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 1/Signature 1
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 1/Signature 2
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 2/Signature 1
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 3/Signature 1
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 3/Signature 2
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 4
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 4/Signature 1
- Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 4/Signature 2
- Age and the aging process significantly alter the small bowel microbiome/Experiment 1
- Age and the aging process significantly alter the small bowel microbiome/Experiment 2
- Age and the aging process significantly alter the small bowel microbiome/Experiment 3
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 1/Signature 1
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 2/Signature 1
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 2/Signature 2
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 4
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 5
- Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 6
- The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1
- The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1/Signature 1
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1/Signature 1
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1/Signature 2
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 2
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 3
- Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 4
- Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 1
- Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 2
- Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 2/Signature 1
- Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 4
- Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 6
- Biliary Microbiota in Choledocholithiasis and Correlation With Duodenal Microbiota
- Biliary Microbiota in Choledocholithiasis and Correlation With Duodenal Microbiota/Experiment 1
- The treatment-naive microbiome in new-onset Crohn's disease/Experiment 1
- The treatment-naive microbiome in new-onset Crohn's disease/Experiment 2
- The treatment-naive microbiome in new-onset Crohn's disease/Experiment 3
- Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease/Experiment 1/Signature 1
- Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease/Experiment 1/Signature 2
- Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 1/Signature 1
- Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 1/Signature 2
- Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 2
- Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 3/Signature 2
- Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 4
- Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease/Experiment 1
- Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease/Experiment 1/Signature 2
- Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1
- Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1/Signature 1
- Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1/Signature 2
- An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation/Experiment 1
- Structural changes in gut microbiome after Ramadan fasting: a pilot study/Experiment 1
- Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms/Experiment 1
- Altered Gut Microbiome in Patients With Dermatomyositis/Experiment 1
- Altered Gut Microbiome in Patients With Dermatomyositis/Experiment 2
- Profiling the Salivary microbiome of the Qatari population/Experiment 1/Signature 1
- Profiling the Salivary microbiome of the Qatari population/Experiment 1/Signature 2
- Profiling the Salivary microbiome of the Qatari population/Experiment 2/Signature 1
- Profiling the Salivary microbiome of the Qatari population/Experiment 2/Signature 2
- Profiling the Salivary microbiome of the Qatari population/Experiment 3/Signature 2
- Profiling the Salivary microbiome of the Qatari population/Experiment 5/Signature 1
- Profiling the Salivary microbiome of the Qatari population/Experiment 5/Signature 2
- Profiling the Salivary microbiome of the Qatari population/Experiment 8
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults/Experiment 1
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults/Experiment 2
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults/Experiment 3
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults/Experiment 4
- Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults/Experiment 5
- Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels
- Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels/Experiment 1/Signature 1
- Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels/Experiment 1/Signature 2
- Alcohol and tobacco consumption affects bacterial richness in oral cavity mucosa biofilms/Experiment 2/Signature 2
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 1
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 2
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 3
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 4
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 5
- Ocular microbiome changes in dry eye disease and meibomian gland dysfunction/Experiment 6
- Comparative portrayal of ocular surface microbe with and without dry eye/Experiment 2/Signature 2
- Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort/Experiment 2/Signature 1
- Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 1
- Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 2
- Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 3
- Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 1
- Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 4/Signature 1
- Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 4/Signature 2
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2
- Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 1/Signature 2
- Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2
- Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2/Signature 1
- Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2/Signature 2
- Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population/Experiment 2
- Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population/Experiment 3
- A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients/Experiment 2
- Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1
- Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1/Signature 1
- Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1/Signature 2
- Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 4/Signature 2
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1/Signature 1
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1/Signature 2
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2/Signature 1
- Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2/Signature 2
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1/Signature 1
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1/Signature 2
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2/Signature 1
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2/Signature 2
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3/Signature 1
- Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3/Signature 2
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 1
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 2
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 3
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 4
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 5
- Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 6
- Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1
- Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1/Signature 1
- Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1/Signature 2
- Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 2
- Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 3
- Characterizing both bacteria and fungi improves understanding of the Arabidopsis root microbiome/Experiment 1
- Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 1/Signature 1
- Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 1/Signature 2
- Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 2/Signature 2
- Gut microbiota display alternative profiles in patients with early-onset colorectal cancer/Experiment 1
- Gut microbiota display alternative profiles in patients with early-onset colorectal cancer/Experiment 1/Signature 1
- The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 1
- The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 2
- Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 3/Signature 1
- Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 4
- Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 4/Signature 1
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 1
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 1/Signature 1
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 1/Signature 2
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2/Signature 1
- Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2/Signature 2
- A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic/Experiment 2/Signature 1
- A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic/Experiment 2/Signature 2
- The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model/Experiment 1
- Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 1/Signature 1
- Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 3
- Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 5/Signature 1
- Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 2
- Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 2/Signature 1
- The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 1
- The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 2/Signature 1
- The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 4/Signature 2
- Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression/Experiment 1/Signature 1
- Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression/Experiment 3
- Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study/Experiment 1
- Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study/Experiment 1/Signature 1
- Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 1
- Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 2
- Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 3
- Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 1/Signature 1
- Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 1/Signature 2
- Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2
- Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2/Signature 1
- Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2/Signature 2
- The aging mouse microbiome has obesogenic characteristics/Experiment 1/Signature 1
- Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 3
- Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 3/Signature 2
- Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 4/Signature 2
- Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis/Experiment 1
- Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea/Experiment 2
- Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 1
- Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 2
- Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 2/Signature 2
- Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 3
- Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 4
- Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 2/Signature 1
- Changes in salivary microbiota due to gastric cancer resection and its relation to gastric fluid microbiota/Experiment 2
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 1/Signature 1
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 1/Signature 2
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 2
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 2/Signature 1
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 4/Signature 1
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 4/Signature 2
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 5
- Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 7
- Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 5/Signature 2
- Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 1
- Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 2
- Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 1/Signature 2
- Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 2
- Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 2/Signature 1
- Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 5
- Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 6/Signature 1
- Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 1
- Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 2
- Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 2
- Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes/Experiment 1
- Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non-segmental vitiligo/Experiment 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2/Signature 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2/Signature 2
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 3/Signature 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 4
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 4/Signature 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5/Signature 1
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5/Signature 2
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 6
- COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 6/Signature 2
- Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 3/Signature 2
- Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 3
- Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 3/Signature 1
- Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 4
- Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 5
- Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 6
- Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 7
- Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population/Experiment 1
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 1/Signature 1
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 2
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 2/Signature 1
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 3
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 3/Signature 1
- Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 9/Signature 1
- Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 1/Signature 1
- Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye/Experiment 3/Signature 1
- The gut microbiome in social anxiety disorder: evidence of altered composition and function/Experiment 1
- Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 1
- Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 2
- Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 3
- Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut/Experiment 4
- Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer/Experiment 1
- Identifying microbial signatures for patients with postmenopausal osteoporosis using gut microbiota analyses and feature selection approaches/Experiment 1
- Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 1/Signature 1
- Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 6/Signature 1
- Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 6/Signature 2
- Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls
- Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls/Experiment 1
- Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls/Experiment 1/Signature 2
- Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1
- Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1/Signature 1
- Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1/Signature 2
- Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 2/Signature 1
- Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 2/Signature 2
- Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 1
- Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 2
- Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 1/Signature 1
- Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 2/Signature 1
- Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 3
- Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis
- Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 2/Signature 1
- Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 2/Signature 2
- Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 1
- PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation
- Alterations in the Gut Microbiota and Metabolomics of Seafarers after a Six-Month Sea Voyage/Experiment 1
- Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 1
- Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 1/Signature 2
- Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 4
- Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 6
- Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 7/Signature 1
- Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 1
- Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 2
- Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 3
- Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease/Experiment 1
- Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 2/Signature 2
- Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 1
- Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 1/Signature 2
- Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 2
- Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 2/Signature 2
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1/Signature 1
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1/Signature 2
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2/Signature 1
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2/Signature 2
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3/Signature 1
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3/Signature 2
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 6
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 7
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 8
- Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 9
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1/Signature 1
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1/Signature 2
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 2
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 3
- A metagenomic study of the gut microbiome in Behcet's disease/Experiment 3/Signature 1
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 1/Signature 2
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 2/Signature 1
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4/Signature 1
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4/Signature 2
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5/Signature 1
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5/Signature 2
- Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 6/Signature 1
- Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation/Experiment 1/Signature 1
- Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 2/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 3
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 3/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 4
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 4/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 4/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 5
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 5/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 5/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 6
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 6/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 7
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 7/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 7/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 8
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 8/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 8/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 9
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 9/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 9/Signature 2
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 10
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 10/Signature 1
- Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients/Experiment 10/Signature 2
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 1/Signature 1
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 1/Signature 2
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 2/Signature 1
- Analysis on the change of gut microbiota and metabolome in lung transplant patients
- Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis/Experiment 1
- Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment/Experiment 14
- Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 1
- Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 2/Signature 2
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 1
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 1/Signature 1
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 1/Signature 2
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 2
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 2/Signature 1
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 3
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 3/Signature 1
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 3/Signature 2
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 4
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 4/Signature 2
- The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 5
- Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing/Experiment 1/Signature 1
- Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing/Experiment 1/Signature 2
- The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 1/Signature 1
- The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 1/Signature 2
- The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 2/Signature 1
- The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 2/Signature 2
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 4
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5/Signature 1
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 5/Signature 2
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6/Signature 1
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 6/Signature 2
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7/Signature 1
- Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 7/Signature 2
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 1
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 2
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2/Signature 1
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 1
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 2
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 4
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 4/Signature 1
- Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 4/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 1/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 2/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 3/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 4/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 5/Signature 2
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6/Signature 1
- Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission/Experiment 6/Signature 2
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1/Signature 1
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 1/Signature 2
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 2
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3/Signature 1
- External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells/Experiment 3/Signature 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1/Signature 1
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1/Signature 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 2/Signature 1
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 2/Signature 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 3
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 3/Signature 1
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 3/Signature 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 4
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 4/Signature 1
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 4/Signature 2
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 5
- Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 5/Signature 1
- Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer/Experiment 2
- Insights into estrogen impact in oral health & microbiome in COVID-19/Experiment 1
- Characterization of oral bacterial and fungal microbiome in recovered COVID-19 patients/Experiment 1
- Western Kenyan Anopheles gambiae showing intense permethrin resistance harbour distinct microbiota/Experiment 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 1/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 1/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 2/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 2/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 3
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 3/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 3/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 4
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 4/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 4/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 5
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 5/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 5/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 6
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 6/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 6/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 7
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 7/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 8
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 8/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 9
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 9/Signature 1
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 10
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 10/Signature 2
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 11
- Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy/Experiment 11/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 1/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 2/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 3/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 4/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 5/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 6
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 6/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 7
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 7/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 7/Signature 2
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 8
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 8/Signature 1
- Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging/Experiment 8/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 11
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 11/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 11/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 12
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 12/Signature 1
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 12/Signature 2
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 13
- Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 13/Signature 1
- Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester
- Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester/Experiment 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 1/Signature 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 1/Signature 2
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 2
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 2/Signature 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 2/Signature 2
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 3
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 4
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 5
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 5/Signature 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 5/Signature 2
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 6
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 6/Signature 1
- Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles/Experiment 6/Signature 2
- Alteration in gut mycobiota of patients with polycystic ovary syndrome/Experiment 1
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 1
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 2
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 1
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 2
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6
- Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6/Signature 1
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 1
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 1/Signature 1
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 1/Signature 2
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 2
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 2/Signature 1
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 2/Signature 2
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 3
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 3/Signature 1
- A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease/Experiment 3/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6/Signature 1
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6/Signature 2
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 7
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 8
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 9
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 10
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 11
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 12
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 13
- Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 14
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 1
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 1/Signature 1
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 1/Signature 2
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 2
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 2/Signature 1
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 2/Signature 2
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 3
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 3/Signature 1
- Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species/Experiment 3/Signature 2
- The role of Bifidobacterium genus in modulating the neonate microbiota: implications for antibiotic resistance acquisition in early life/Experiment 1
- The role of Bifidobacterium genus in modulating the neonate microbiota: implications for antibiotic resistance acquisition in early life/Experiment 2
- Transplantation of gut microbiota derived from patients with schizophrenia induces schizophrenia-like behaviors and dysregulated brain transcript response in mice/Experiment 2
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 1
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 1/Signature 1
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 1/Signature 2
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 2
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 2/Signature 1
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 2/Signature 2
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 3
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 3/Signature 1
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 3/Signature 2
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 4
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 4/Signature 1
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults/Experiment 4/Signature 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 1/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 1/Signature 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 2/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 2/Signature 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 3
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 3/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 3/Signature 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 4
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 4/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 4/Signature 2
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 5
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 5/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 6
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 6/Signature 1
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 7
- Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach/Experiment 7/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1/Signature 2
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 2
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 2/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 3
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 3/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 4
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 4/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6/Signature 1
- Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6/Signature 2
- Depletion of the paternal gut microbiome alters sperm small RNAs and impacts offspring physiology and behavior in mice
- Depletion of the paternal gut microbiome alters sperm small RNAs and impacts offspring physiology and behavior in mice/Experiment 1
- Depletion of the paternal gut microbiome alters sperm small RNAs and impacts offspring physiology and behavior in mice/Experiment 1/Signature 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 1/Signature 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 1/Signature 2
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 2
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 2/Signature 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 2/Signature 2
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 3
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 3/Signature 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 3/Signature 2
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 4
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 4/Signature 1
- The intensive physical activity causes changes in the composition of gut and oral microbiota/Experiment 4/Signature 2
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 1/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 1/Signature 2
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 2
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 2/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 2/Signature 2
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 4
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 4/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 4/Signature 2
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 5
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 5/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 5/Signature 3
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 6
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 6/Signature 1
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 7
- Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 7/Signature 1
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 1
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 1/Signature 1
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2/Signature 1
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2/Signature 2
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3/Signature 1
- Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3/Signature 2
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 1
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 1/Signature 1
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 1/Signature 2
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 2
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 2/Signature 1
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 2/Signature 2
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 3
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 3/Signature 1
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 3/Signature 2
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 4
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 4/Signature 1
- Immune activation and inflammation in lactating women on combination antiretroviral therapy: role of gut dysfunction and gut microbiota imbalance/Experiment 4/Signature 2
- Risk factors for type 1 diabetes, including environmental, behavioural and gut microbial factors: a case-control study
- Risk factors for type 1 diabetes, including environmental, behavioural and gut microbial factors: a case-control study/Experiment 1
- Risk factors for type 1 diabetes, including environmental, behavioural and gut microbial factors: a case-control study/Experiment 1/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 1/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 1/Signature 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 2/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 2/Signature 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 3
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 3/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 3/Signature 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 4
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 4/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 4/Signature 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 5
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 5/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 5/Signature 2
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 6
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 6/Signature 1
- Integrating metagenomics with metabolomics for gut microbiota and metabolites profiling in acute pancreatitis/Experiment 6/Signature 2
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 1
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 1/Signature 1
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 2/Signature 1
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 2/Signature 2
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 3
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 3/Signature 1
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 4
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 4/Signature 1
- Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course/Experiment 4/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 1/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 1/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 2/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 2/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 3
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 3/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 3/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 4
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 4/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 4/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 5
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 5/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 5/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 6
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 6/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 6/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 7
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 7/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 7/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 8
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 8/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 8/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 9
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 9/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 9/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 10
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 10/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 10/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 11
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 11/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 11/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 12
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 12/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 12/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 13
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 13/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 13/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 14
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 14/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 14/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 15
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 15/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 15/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 16
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 16/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 17
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 17/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 17/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 18
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 18/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 18/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 19
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 19/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 19/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 20
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 20/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 20/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 21
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 21/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 21/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 22
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 22/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 23
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 23/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 24
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 24/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 25
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 25/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 25/Signature 2
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 26
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 26/Signature 1
- Comparative Studies of the Gut Microbiota in the Offspring of Mothers With and Without Gestational Diabetes/Experiment 26/Signature 2
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 1
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 1/Signature 1
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 1/Signature 2
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 2
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 2/Signature 1
- The Potential of Gut Microbiota in Prediction of Stroke-Associated Pneumonia/Experiment 2/Signature 2
- Role of the Gut Microbiota in the Increased Infant Body Mass Index Induced by Gestational Diabetes Mellitus
- Role of the Gut Microbiota in the Increased Infant Body Mass Index Induced by Gestational Diabetes Mellitus/Experiment 1
- Role of the Gut Microbiota in the Increased Infant Body Mass Index Induced by Gestational Diabetes Mellitus/Experiment 1/Signature 1
- Role of the Gut Microbiota in the Increased Infant Body Mass Index Induced by Gestational Diabetes Mellitus/Experiment 1/Signature 2
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 1
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 1/Signature 1
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 1/Signature 2
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 2
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 2/Signature 1
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 2/Signature 6
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 3
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 3/Signature 1
- Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals/Experiment 3/Signature 2
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 1
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 1/Signature 1
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 1/Signature 2
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 2
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 2/Signature 1
- Bacteroides uniformis degrades β-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis/Experiment 2/Signature 2
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 1
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 1/Signature 1
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 1/Signature 2
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 2
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 2/Signature 1
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 2/Signature 2
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 3
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 3/Signature 1
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 3/Signature 2
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 4
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 4/Signature 1
- Preconception helminth infection alters offspring microbiota and immune subsets in a mouse model/Experiment 4/Signature 2
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 1
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 1/Signature 1
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 2
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 2/Signature 1
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 3
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 3/Signature 1
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 4
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 4/Signature 1
- Insights into the vaginal microbiome in a diverse group of women of African, Asian and European ancestries/Experiment 5/Signature 1
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 1
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 1/Signature 1
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 1/Signature 2
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 2
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 2/Signature 1
- Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese/Experiment 2/Signature 2
- The skin microbiome stratifies patients with cutaneous T cell lymphoma and determines event-free survival
- The skin microbiome stratifies patients with cutaneous T cell lymphoma and determines event-free survival/Experiment 1
- The skin microbiome stratifies patients with cutaneous T cell lymphoma and determines event-free survival/Experiment 1/Signature 1
- The skin microbiome stratifies patients with cutaneous T cell lymphoma and determines event-free survival/Experiment 1/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 1/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 1/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 2/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 2/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 4
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 4/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 4/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 5
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 5/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 5/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 6
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 6/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 6/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 7
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 7/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 7/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 8
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 8/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 8/Signature 2
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 9
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 9/Signature 1
- Oral and gut microbial profiling in periodontitis and Parkinson's disease/Experiment 9/Signature 2
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1/Signature 1
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 1/Signature 2
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2/Signature 1
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 2/Signature 2
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 3
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 3/Signature 1
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 3/Signature 2
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4/Signature 1
- Gut microbiota patterns associated with duration of diarrhea in children under five years of age in Ethiopia/Experiment 4/Signature 2
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1/Signature 1
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1/Signature 2
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2/Signature 1
- Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2/Signature 2
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 1
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 1/Signature 1
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 1/Signature 2
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 2
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 2/Signature 1
- Publisher Correction: Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study/Experiment 2/Signature 3
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 1/Signature 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 1/Signature 2
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2/Signature 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2/Signature 2
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 3
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 3/Signature 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 4
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 4/Signature 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 5
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 5/Signature 1
- Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 5/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 1/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 1/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 2/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 2/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 3
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 3/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 4
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 4/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 4/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 5
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 5/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 5/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 6
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 6/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 6/Signature 2
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 7
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 7/Signature 1
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial/Experiment 7/Signature 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 1/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 2/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 3
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 3/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 4
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 4/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 5
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 5/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 5/Signature 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 6
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 6/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 6/Signature 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 7
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes/Experiment 7/Signature 1
- Diet at birth is critical for healthy growth, independent of effects on the gut microbiota
- Diet at birth is critical for healthy growth, independent of effects on the gut microbiota/Experiment 1
- Diet at birth is critical for healthy growth, independent of effects on the gut microbiota/Experiment 1/Signature 1
- Diet at birth is critical for healthy growth, independent of effects on the gut microbiota/Experiment 1/Signature 2
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1/Signature 1
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1/Signature 4
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2/Signature 1
- Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2/Signature 2
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion/Experiment 1
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion/Experiment 1/Signature 1
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion/Experiment 1/Signature 2
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion/Experiment 2
- Gut microbiota-derived gamma-aminobutyric acid improves host appetite by inhibiting satiety hormone secretion/Experiment 2/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 1/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 2/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 2/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 3
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 3/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 3/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 4
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 4/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 4/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 5
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 5/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 6
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 6/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 7
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 7/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 7/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 8
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 8/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 8/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 9
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 9/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 10
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 10/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 11
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 11/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 12
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 12/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 12/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 13
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 13/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 13/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 14
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 14/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 14/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 15
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 15/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 15/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 16
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 16/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 16/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 17
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 17/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 17/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 18
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 18/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 18/Signature 2
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 19
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 19/Signature 1
- Gut metagenomes of Asian octogenarians reveal metabolic potential expansion and distinct microbial species associated with aging phenotypes/Experiment 19/Signature 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 1/Signature 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 1/Signature 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 2/Signature 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 2/Signature 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 3
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 3/Signature 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 3/Signature 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 4
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 4/Signature 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 4/Signature 2
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 5
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 5/Signature 1
- Gut microbiome and serum metabolome alterations associated with lactose intolerance (LI): a case‒control study and paired-sample study based on the American Gut Project (AGP)/Experiment 5/Signature 2
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 1
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 1/Signature 1
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 1/Signature 4
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 2
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 2/Signature 1
- Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection/Experiment 2/Signature 2
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 1
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 1/Signature 1
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 1/Signature 2
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 2
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 2/Signature 1
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 2/Signature 2
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 3
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 3/Signature 1
- Association between clinical and environmental factors and the gut microbiota profiles in young South African children/Experiment 3/Signature 2
- Gut microbiota alterations in response to sleep length among African-origin adults
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1/Signature 1
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1/Signature 2
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 2
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 2/Signature 1
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3/Signature 1
- Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3/Signature 2
- Comparison of targeted metagenomics and IS-Pro methods for analysing the lung microbiome
- Comparison of targeted metagenomics and IS-Pro methods for analysing the lung microbiome/Experiment 1
- Comparison of targeted metagenomics and IS-Pro methods for analysing the lung microbiome/Experiment 1/Signature 1
- Comparison of targeted metagenomics and IS-Pro methods for analysing the lung microbiome/Experiment 1/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 2/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 3
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 3/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 5
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 6
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 7
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 7/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 12
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 12/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 13
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 13/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 14
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 14/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 22
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 22/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 23
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 23/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 25
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 25/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 27
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 27/Signature 2
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 28
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 28/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 29
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 29/Signature 1
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 30
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 30/Signature 1
- Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents
- Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1
- Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1/Signature 1
- Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1/Signature 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1/Signature 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2/Signature 1
- Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2/Signature 2
- Faecal Microbiota Characterisation of Potamochoerus porcus Living in a Controlled Environment
- Faecal Microbiota Characterisation of Potamochoerus porcus Living in a Controlled Environment/Experiment 1
- Faecal Microbiota Characterisation of Potamochoerus porcus Living in a Controlled Environment/Experiment 1/Signature 1
- Faecal Microbiota Characterisation of Potamochoerus porcus Living in a Controlled Environment/Experiment 1/Signature 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1/Signature 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1/Signature 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 3
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 3/Signature 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 3/Signature 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 4
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 4/Signature 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 4/Signature 2
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 5
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 5/Signature 1
- Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 5/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 3
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 3/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 7
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 7/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 8
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 8/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 10
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 10/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 12
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 12/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 14
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 14/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 15
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 15/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 16
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 16/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 17
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 17/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 25
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 25/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26/Signature 2
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 27
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 27/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 28
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 28/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 29
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 29/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 30
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 30/Signature 1
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 31
- The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 31/Signature 1
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1/Signature 1
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1/Signature 2
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 2
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 2/Signature 1
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3/Signature 1
- Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 1/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 1/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 2/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 2/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 3
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 3/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 3/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 4
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 4/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 4/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 5
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 5/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 5/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 6
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 6/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 6/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 7
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 7/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 7/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 8
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 8/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 8/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 9
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 9/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 9/Signature 2
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 10
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 10/Signature 1
- Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum/Experiment 10/Signature 2
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 1
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 1/Signature 1
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 1/Signature 2
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 2
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 2/Signature 1
- Distinctive Gut Microbiota Alteration Is Associated with Poststroke Functional Recovery: Results from a Prospective Cohort Study/Experiment 2/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 3
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 3/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 3/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 4
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 4/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 4/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 5
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 5/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 5/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 6
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 6/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 6/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 7
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 7/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 7/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 8
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 8/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 8/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 9
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 9/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 9/Signature 2
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 10
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 10/Signature 1
- Sampling from four geographically divergent young female populations demonstrates forensic geolocation potential in microbiomes/Experiment 10/Signature 2
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 1
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 1/Signature 1
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 1/Signature 2
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 2
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 2/Signature 1
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 2/Signature 2
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 3
- The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 3/Signature 1
- Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis
- Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis/Experiment 1
- Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis/Experiment 1/Signature 1
- Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis/Experiment 1/Signature 2
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1/Signature 1
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1/Signature 2
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 2
- Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 2/Signature 1
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy/Experiment 1
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy/Experiment 1/Signature 1
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy/Experiment 1/Signature 2
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy/Experiment 3
- Sustained gut dysbiosis and intestinal inflammation show correlation with weight gain in person with chronic HIV infection on antiretroviral therapy/Experiment 3/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 4
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 4/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 5
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 5/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 7
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 7/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 8
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 8/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12/Signature 2
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13/Signature 1
- Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13/Signature 2
- Inactivation of the MSTN gene expression changes the composition and function of the gut microbiome in sheep
- Study 1182/Experiment 1
- Study 1182/Experiment 1/Signature 1
- Study 1182/Experiment 1/Signature 2
- Study 1182/Experiment 2
- Study 1182/Experiment 2/Signature 1
- Study 1182/Experiment 2/Signature 2
- Study 1182/Experiment 3
- Study 1182/Experiment 3/Signature 1
- Study 1182/Experiment 3/Signature 2
- Study 1182/Experiment 4
- Study 1182/Experiment 4/Signature 1
- Study 1182/Experiment 4/Signature 2
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 1
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 1/Signature 1
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 1/Signature 2
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 2
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 2/Signature 1
- Microbial gut evaluation in an angolan paediatric population with sickle cell disease/Experiment 2/Signature 2
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1/Signature 1
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1/Signature 2
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 2
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 2/Signature 1
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3/Signature 1
- The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3/Signature 2
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1/Signature 1
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1/Signature 2
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2/Signature 1
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2/Signature 2
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3/Signature 1
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3/Signature 2
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4/Signature 1
- Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 8
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 8/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 9
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 9/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 10
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 10/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 10/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 11
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 11/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 12
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 12/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 13
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 13/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 14
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 14/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 14/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 15
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 15/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 16
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 16/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 16/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 17
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 17/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 17/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 18
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 18/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 18/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 19
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 19/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 19/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 20
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 20/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 20/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 21
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 21/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 21/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 22
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 22/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 22/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 23
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 23/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 23/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 24
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 24/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 24/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 25
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 25/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 25/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 26
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 26/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 26/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 27
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 27/Signature 1
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 27/Signature 2
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 28
- Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 28/Signature 1
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1/Signature 1
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1/Signature 2
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2/Signature 1
- A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2/Signature 2
- Changes in the vaginal microbiota across a gradient of urbanization
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1/Signature 2
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 2
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 2/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 3
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 3/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 4
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 4/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 5
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 5/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6/Signature 2
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 7
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 7/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 8
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 8/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 9
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 9/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 10
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 10/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11/Signature 2
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 13
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 13/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 14
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 14/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 14/Signature 2
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 15
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 15/Signature 1
- Changes in the vaginal microbiota across a gradient of urbanization/Experiment 15/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7/Signature 2
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8/Signature 1
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8/Signature 2
- Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies
- Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1
- Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1/Signature 1
- Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1/Signature 2
- Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa
- Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa/Experiment 1
- Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa/Experiment 1/Signature 1
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1/Signature 1
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1/Signature 2
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 2
- Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 2/Signature 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1/Signature 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1/Signature 2
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 2
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 2/Signature 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 3
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 3/Signature 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4/Signature 1
- The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6/Signature 2
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7/Signature 1
- Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7/Signature 2
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1/Signature 1
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1/Signature 2
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2/Signature 1
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2/Signature 2
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 3
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 3/Signature 1
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 3/Signature 2
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 4
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 4/Signature 1
- Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 4/Signature 2
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1/Signature 2
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1/Signature 3
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3/Signature 1
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3/Signature 2
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4/Signature 1
- Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4/Signature 2
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1/Signature 1
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1/Signature 2
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2/Signature 1
- Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2/Signature 2
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1/Signature 1
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1/Signature 2
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2/Signature 1
- Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2/Signature 2
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 1/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 2
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 2/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 3
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 3/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 4
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 4/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5/Signature 2
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6/Signature 1
- Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6/Signature 2
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1/Signature 1
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1/Signature 2
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3/Signature 1
- Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3/Signature 2
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 1/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 2
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 2/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 3
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 3/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 4
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 4/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 5
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 5/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 6
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 6/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 7
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 7/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 8
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 8/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 9
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 9/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10/Signature 2
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11/Signature 1
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11/Signature 2
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 12
- Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 12/Signature 1
- Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice
- Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1
- Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1/Signature 1
- Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30/Signature 2
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31/Signature 1
- Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31/Signature 2
- Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies
- Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1
- Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1/Signature 1
- Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1/Signature 2
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1/Signature 1
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1/Signature 2
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 2
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 2/Signature 1
- Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 2/Signature 2
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 1
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 1/Signature 1
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2/Signature 1
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2/Signature 2
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3/Signature 1
- Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 1/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 1/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 6
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 6/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 6/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7/Signature 2
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 8
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 8/Signature 1
- Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 8/Signature 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1/Signature 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2/Signature 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3/Signature 3
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4/Signature 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5/Signature 2
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6/Signature 1
- Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6/Signature 2
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 7
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 7/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 8
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 8/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 9
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 9/Signature 1
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 10
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 10/Signature 1
- Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer
- Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1
- Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1/Signature 1
- Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1/Signature 2
- Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 2
- Tumor microbial diversity and compositional differences among women in Botswana with